CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment

Multiple Sclerosis Journal

Volumn 17, Issue 5, 2011, Pages 556-566

  Frisullo, Giovanni ^a   Iorio, Raffaele ^a   Plantone, Domenico ^a   Marti, Alessandro ^a   Nociti, Viviana ^a,b   Patanella, Agata Katia ^a,b   Batocchi, Anna Paola ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

B cells; Monocytes; Multiple sclerosis; Natalizumab; PSTAT1; PSTAT3; T cells; T bet

Indexed keywords

BETA1A INTERFERON; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; T BOX TRANSCRIPTION FACTOR; T BOX TRANSCRIPTION FACTOR TBX21; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BIOACCUMULATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RELAPSE; REMISSION; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; CELL CULTURE; CHI SQUARE DISTRIBUTION; DRUG EFFECT; IMMUNOLOGY; ITALY; MIDDLE AGED; PHOSPHORYLATION; RECURRENT DISEASE; T LYMPHOCYTE SUBPOPULATION; TIME; TREATMENT OUTCOME; UPREGULATION;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHOSPHORYLATION; RECURRENCE; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 80053409357     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510392263     Document Type: Article

References (41)

1. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356: 2622-2629. (Pubitemid 46961007)
2. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, et al. NZB effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59: 748-755.
3. Bielekova B and Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology 2010; 74(Suppl 1): S31-S40.
4. Del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to NZB. Arch Neurol 2008; 65: 1596-1603.
5. Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with NZB. Ann Neurol 2006; 59: 743-747. (Pubitemid 43673151)
6. Sato T, Tachibana K, Nojima Y, D'Avirro N and Morimoto C. Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J Immunol 1995; 155: 2938-2947.
7. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. AFFIRM Investigators. A randomized, placebo-controlled trial of NZB for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
8. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. SENTINEL Investigators. NZB plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
9. Khademi M, Stol D, Olsson T and Wallström E. Induction of systemic TNFalpha in NZB-treated multiple sclerosis. Eur J Neurol 2008; 15: 309-312. (Pubitemid 351257912)
10. Kivisäkk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, et al. NZB treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009; 72: 1922-1930.
11. Stenner MP, Waschbisch A, Buck D, Doerck S, Einsele H, Toyka KV, et al. Effects of NZB treatment on Foxp3+ T regulatory cells. PLoS One 2008; 3: e3319.
12. Hohlfeld R and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004; 101(Suppl. 2): 14599-14606. (Pubitemid 39346730)
13. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-472. (Pubitemid 29382036)
14. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM and Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70: 1150-1151. (Pubitemid 351464749)
15. Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, et al. Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated. Ann Neurol 2010; 68: 392-395.
16. Frisullo G, Angelucci F, Caggiula M, Nociti V, Iorio R, Patanella AK, et al. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J Neurosci Res 2006; 84: 1027-1036. (Pubitemid 44521047)
17. Frisullo G, Nociti V, Iorio R, Patanella AK, Bianco A, Caggiula M, et al. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin Immunol 2007; 124: 284-293. (Pubitemid 47247610)
18. Frisullo G, Nociti V, Iorio R, Patanella AK, Caggiula M, Marti A, et al. Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients. Immunology 2009; 127: 418-428.
19. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
20. Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R and Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350-1354.
21. Putzki N, Baranwal MK, Tettenborn B, Limmroth V and Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol 2010; 63: 311-317.
22. Friese MA and Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol 2009; 66: 132-141.
23. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG and Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655-669.
24. Meinl E, Derfuss T, Krumbholz M, Pröbstel AK and Hohlfeld R. Humoral autoimmunity in multiple sclerosis. J Neurol Sci 2010; doi:10.1016/j.jns2010. 08.009.
25. Schulz EG, Mariani L, Radbruch A and Höfer T. Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin- 12. Immunity 2009; 30: 673-683.
26. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 2001; 98: 15137-15142. (Pubitemid 34013982)
27. Mayer KD, Mohrs K, Reiley W, Wittmer S, Kohlmeier JE, Pearl JE, et al. Cutting edge: T-bet and IL-27R are critical for in vivo IFN-gamma production by CD8 T cells during infection. J Immunol 2008; 180: 693-697.
28. Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 2009; 206: 51-59.
29. Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, Racke MK, et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 2007; 178: 1341-1348. (Pubitemid 46154603)
30. Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010; 32: 605-615.
31. Bettelli E, Korn T, Oukka M and Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453: 1051-1057. (Pubitemid 351871737)
32. Harris DP, Goodrich S, Gerth AJ, Peng SL and Lund FE. Regulation of INF-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol 2005; 174: 6781-6790. (Pubitemid 40705641)
33. Peng SL. The T-box transcription factor T-bet in immunity and autoimmunity. Cell Mol Immunol 2006; 3: 87-95.
34. Najjar I, Deglesne PA, Schischmanoff PO, Fabre EE, Boisson-Dupuis S, Nimmerjahn F, et al. STAT1-dependent IgG cell-surface expression in a human B cell line derived from a STAT1-deficient patient. J Leukoc Biol 2010; 87: 1145-1152.
35. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing longlived antibody responses in humans. J Exp Med 2010; 207: 155-171.
36. Krumbholz M, Faber H, Steinmeyer F, Hoffmann LA, Kümpfel T, Pellkofer H, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008; 131: 1455-1463. (Pubitemid 351806460)
37. Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, et al. T-bet is essential for encephalitogenicity of both \hfill Th1 and Th17 cells. J Exp Med 2009; 206: 1549-1564.
38. Abromson-Leeman S, Bronson RT and Dorf ME. Encephalitogenic T cells that stably express both T-bet and ROR gamma t consistently produce IFNgamma but have a spectrum of IL-17 profiles. J Neuroimmunol 2009; 215: 10-24.
39. Liu X, Lee YS, Yu CR and Egwuagu CE. Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol 2008; 180: 6070-6076.
40. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH and Kuchroo VK. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 2004; 200: 79-87. (Pubitemid 38924730)
41. Hori S, Nomura T and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061. (Pubitemid 36222930)